MI-ONESTREAM-SOFTWARE
16.2.2021 12:02:06 CET | Business Wire | Press release
OneStream Software , a leader in corporate performance management (CPM) solutions for mid-sized to very large enterprises, and PwC UK announced today they have entered into a strategic alliance for the UK market. The partnership will leverage PwC’s expertise as a leading business and technology consulting services provider and OneStream’s unified and cloud-based CPM software to support activities ranging from project delivery to marketing and strategic business collaboration.
“The UK is an important market for OneStream Software and we are excited to welcome PwC UK to our partner ecosystem,” said Stephanie Cramp, SVP of Global Alliances at OneStream Software. “We look forward to working with PwC to help organizations in the UK and across the EMEA region conquer complexity and transform their finance processes by leveraging our intelligent finance platform to replace multiple legacy applications, as well as point solutions and spreadsheets.”
As part of the partnership, PwC UK will further develop its OneStream implementation practice to serve joint customers in the UK but also across the EMEA region. PwC UK will also leverage their industry and domain expertise to create compelling industry specific solutions with OneStream for clients across the market.
“We believe that a combination of OneStream’s unified corporate performance management solution alongside PwC’s industry, functional and implementation expertise can be a real enabler to making a step change in process efficiency, cost-effective growth, and improved decision-making for our clients. We are already seeing the benefits of this in a number of our clients and look forward to our continued collaboration with OneStream going forward,” stated Dan Bell, Partner, Enterprise Performance Management Lead, PwC UK.
“We are thrilled about our alliance with PwC UK, specifically due to the domain expertise and best practices this will bring to OneStream customers in this important market,” said Matt Rodgers, Senior Vice President and EMEA Managing Director at OneStream Software. “This partnership will enable OneStream to extend its delivery capabilities in EMEA and supports our mission of delivering 100% customer success worldwide.”
For more information on the PwC UK-OneStream alliance, visit: www.onestreamsoftware.com/about/onestream-partners and https://www.pwc.co.uk/press-room.html .
About OneStream Software
OneStream Software provides a market-leading intelligent finance platform that reduces the complexity of financial operations. OneStream unleashes the power of finance by unifying corporate performance management (CPM) processes such as planning, financial close & consolidation, reporting and analytics through a single, extensible solution. We empower the enterprise with financial and operational insights to support faster and more informed decision-making. All in a cloud platform designed to continually evolve and scale with your organization.
OneStream is an independent software company backed by private equity investor KKR. With over 600 customers, 200 partners and over 700 employees our primary mission is to deliver 100% customer success.
About PwC UK
At PwC, our purpose is to build trust in society and solve important problems
PwC is a network of over 284,000 professionals around the world, of which about 6,400 in Italy, committed to guaranteeing quality in auditing, technological, strategic, legal and tax consulting services for businesses.
Thanks to our sector expertise, we provide complete and tailor-made solutions as well as a wide range of services in an integrated and multidisciplinary way. Our strength is to be able to combine our knowledge of local markets with a global organization.
We are one of the largest professional services networks in the world, but size is only part of who we are; creating value for our customers, our people and the society in which we live and work is at the heart of PwC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005133/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom